Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vivek Pradhan

Showing results (21-30 of 26) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 26 results.
The Lancet. Rheumatology|January 27, 2024
Safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of the oral TYK2 inhibitor PF-06826647 in participants with plaque psoriasis: a phase 1, randomised, double-blind, placebo-controlled, parallel-group studyChristopher Tehlirian, Elena Peeva, Elizabeth Kieras, et al.
The British Journal of Dermatology|August 20, 2022
Efficacy and safety of topical brepocitinib for the treatment of mild-to-moderate atopic dermatitis: a phase IIb, randomized, double-blind, vehicle-controlled, dose-ranging and parallel-group studyMegan N Landis, Mark Arya, Stacy Smith, et al.
Clinical and Translational Science|December 8, 2020
Safety and Pharmacokinetics of the Oral TYK2 Inhibitor PF-06826647: A Phase I, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation StudyRavi Shankar P Singh, Vivek Pradhan, Erika S Roberts, et al.
Journal of Crohn'S & Colitis|March 23, 2019
Molecular Profiling of Ulcerative Colitis Subjects from the TURANDOT Trial Reveals Novel Pharmacodynamic/Efficacy BiomarkersHuanyu Zhou, Li Xi, Daniel Ziemek, et al.
Lancet (London, England)|May 22, 2017
Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trialSéverine Vermeire, William J Sandborn, Silvio Danese, et al.
Journal of Crohn'S & Colitis|September 30, 2017
Effect of PF-00547659 on Central Nervous System Immune Surveillance and Circulating β7+ T Cells in Crohn's Disease: Report of the TOSCA StudyGeert D'Haens, Séverine Vermeire, Harald Vogelsang, et al.
Pageof 3

Showing results (21-30 of 26) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 26 results.
The Lancet. Rheumatology|January 27, 2024
Safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of the oral TYK2 inhibitor PF-06826647 in participants with plaque psoriasis: a phase 1, randomised, double-blind, placebo-controlled, parallel-group studyChristopher Tehlirian, Elena Peeva, Elizabeth Kieras, et al.
The British Journal of Dermatology|August 20, 2022
Efficacy and safety of topical brepocitinib for the treatment of mild-to-moderate atopic dermatitis: a phase IIb, randomized, double-blind, vehicle-controlled, dose-ranging and parallel-group studyMegan N Landis, Mark Arya, Stacy Smith, et al.
Clinical and Translational Science|December 8, 2020
Safety and Pharmacokinetics of the Oral TYK2 Inhibitor PF-06826647: A Phase I, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation StudyRavi Shankar P Singh, Vivek Pradhan, Erika S Roberts, et al.
Journal of Crohn'S & Colitis|March 23, 2019
Molecular Profiling of Ulcerative Colitis Subjects from the TURANDOT Trial Reveals Novel Pharmacodynamic/Efficacy BiomarkersHuanyu Zhou, Li Xi, Daniel Ziemek, et al.
Lancet (London, England)|May 22, 2017
Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trialSéverine Vermeire, William J Sandborn, Silvio Danese, et al.
Journal of Crohn'S & Colitis|September 30, 2017
Effect of PF-00547659 on Central Nervous System Immune Surveillance and Circulating β7+ T Cells in Crohn's Disease: Report of the TOSCA StudyGeert D'Haens, Séverine Vermeire, Harald Vogelsang, et al.
Pageof 3